{"filing":{"accession_number":"0001185185-26-002808","cik":"0001326205","ticker":"IGC","company_name":"IGC Pharma, Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"igc8k070626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526002808/igc8k070626.htm"},"events":[{"id":17044,"run_id":15260,"accession_number":"0001185185-26-002808","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"IGC Pharma issued 4,274,853 shares of common stock to executive officers (CEO Ram Mukunda and CFO Claudia Grimaldi) in a debt-for-equity conversion, canceling $1,154,210 in outstanding obligations. The unregistered private placement under Section 4(a)(2) of the Securities Act represents a material dilutive equity transaction affecting shareholder ownership structure and executive compensation.","company_name":"IGC Pharma, Inc.","ticker":"IGC","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15341,"accession_number":"0001185185-26-002808","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"IGC Pharma issued 4,274,853 shares of common stock (2,226,475 to CEO Ram Mukunda and 2,048,378 to PFO Claudia Grimaldi) in exchange for cancellation of $1,154,210 in outstanding obligations. The issuance at $0.27 per share represents a dilutive equity transaction that increases share count and reduces liabilities. While structured as debt-for-equity conversion rather than a cash raise, the material increase in shares outstanding and the involvement of executive officers make this a significant capital event affecting shareholder equity and ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:47:11.907560+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15342,"accession_number":"0001185185-26-002808","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered private sale of common stock to executive officers (Mr. Mukunda and Ms. Grimaldi) under Section 4(a)(2) of the Securities Act, with shares issued as restricted securities. This is a classic dilutive equity issuance to insiders, material to investors assessing ownership dilution and executive compensation arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:47:11.907560+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15341,"accession_number":"0001185185-26-002808","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"IGC Pharma issued 4,274,853 shares of common stock (2,226,475 to CEO Ram Mukunda and 2,048,378 to PFO Claudia Grimaldi) in exchange for cancellation of $1,154,210 in outstanding obligations. The issuance at $0.27 per share represents a dilutive equity transaction that increases share count and reduces liabilities. While structured as debt-for-equity conversion rather than a cash raise, the material increase in shares outstanding and the involvement of executive officers make this a significant capital event affecting shareholder equity and ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:47:11.907560+00:00","company_name":"IGC Pharma, Inc.","ticker":"IGC","filing_date":"2026-07-06"},{"id":15342,"accession_number":"0001185185-26-002808","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered private sale of common stock to executive officers (Mr. Mukunda and Ms. Grimaldi) under Section 4(a)(2) of the Securities Act, with shares issued as restricted securities. This is a classic dilutive equity issuance to insiders, material to investors assessing ownership dilution and executive compensation arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:47:11.907560+00:00","company_name":"IGC Pharma, Inc.","ticker":"IGC","filing_date":"2026-07-06"}]}